AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06710769 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ovarian tissue removal will be performed laparoscopically
Description: under general anesthesia concomitantly with another scheduled procedure if possible. Following removal, ovarian tissue will be shipped to University of Pittsburg Medical Center, Magee-Womens Research Institute for processing. Freezing and storing techniques will be in accordance with FDA regulations for reproductive tissues, guidelines of the American Association of Tissues Banks and any other applicable federal, state and local regulations. The tissue will be carefully separated dividing the cortex from the medulla. The cortex will then be cryopreserved for long term storage. The medulla will be shipped overnight back to the PCH Department of Pathology for histological evaluation. If pathology finds evidence of cancer in the ovarian tissue provided, they may request that all of the patient's tissue be returned to pathology for a more detailed examination, which may eliminate the tissue available for the patient's future use.
Study NCT03223805 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Respiratory Distress Symptom Intervention
Description: The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required
Study NCT03223805 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Distress Symptom Intervention
Description: The RDSI comprises of four components~1. Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety~2. Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath~3. Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief~4. Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required
Study NCT03333889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vita Enamic hybrid crown
Description: hybrid ceramic material in the form of mesoblocks where the ceramic block is attached to a ti base .The whole assembly is screw retained superstructure.
Study NCT03333889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: emax hybrid crown
Description: high srength glass ceramic that can be milled in sections up to 1mm .
Study NCT03258229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Angelica gigas N. extract
Description: capsules(2cap/d, 1,000mg/d) for 8 weeks.
Study NCT03258229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 8 weeks
Study NCT01251211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
Study NCT01251211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: botulinum toxin type A
Description: BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
Study NCT00397046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study NCT02931227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: temperature obtained by the non-invasive method of zero-heat flux
Study NCT02931227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal temperature
Study NCT02931227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intracerebral temperature
Study NCT02931227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arterial temperature
Study NCT04059822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slow and deep breathing
Description: Please see arm description
Study NCT00532415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide Injectable Suspension
Description: Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
Study NCT04487821 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cawthorne Cooksey Exercises
Description: Activity sitting on the Exercise Ball swing (eye movements, first slow and then fast)~Swing sitting activity (head movements, first slow then fast - eyes open and eyes closed)~Trunk activities focusing on balance~Dynamic balance activity focusing on standing
Study NCT02414841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonapanitase
Study NCT06745856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Subconjunctival, peroperative, application of 50mg/ml concentration of 5-fluoruracil.
Study NCT06745856 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subconjunctival, peroperative application of normal saline (NaCl 0.9%)
Study NCT03709953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg，po，QD； 28 days every cycle
Study NCT02414841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02943096 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CocoaVia
Description: Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
Study NCT02943096 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill).
Study NCT06678763 — intervention group
Intervention type: PROCEDURE
Intervention: CRS-HIPEC
Description: Patients with uterine leiomyosarcoma who received unprotected morcellation were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with docetaxel and gemcitabine.
Study NCT03439085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
Description: Given IM and via electroporation
Study NCT03439085 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV
Study NCT03105193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Saline bolus and infusion
Description: Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
Study NCT03105193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP Saline bolus and infusion
Description: Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Study NCT01273558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg capsule taken orally (by mouth) on Days Days 1-8
Study NCT02897284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness 8 weeks
Description: 8 sessions of mindfulness
Study NCT03105193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV lignocaine bolus and infusion
Description: Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
Study NCT03105193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP Lignocaine bolus and infusion
Description: Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
Study NCT04440358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate BBBD
Description: BBB opening via Exablate Neuro Type 2 system to deliver carboplatin
Study NCT04440358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin infusion on the day of Exablate BBBD procedure to treat cancerous cells in the brain
Study NCT04003441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet A
Description: Period 1: DWP14012 tablet B Period 2: DWP14012 tablet A
Study NCT04003441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 tablet B
Description: Period 1: DWP14012 tablet A Period 2: DWP14012 tablet B
Study NCT02232945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo of oseltamivir phosphate
Study NCT02232945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of oseltamivir phosphate
Study NCT02232945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oseltamivir phosphate
Study NCT02232945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Banlangen (Radix Isatidis) granules
Study NCT02897284 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness 2 weeks
Description: 2 sessions of mindfulness
Study NCT03661554 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T Cells
Description: The Chinese name of CAR-T cells is chimeric antigen receptor T cells. It is through gene transfection technology, so that patients with T lymphocytes can carry B cell-specific antigens, so that T lymphocytes can selectively kill B lymphocyte-derived tumor cells.
Study NCT03275103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cevostamab
Description: Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
Study NCT02365688 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial bolus pre-incision
Description: Measured hemodynamic response to pre-incision bolus
Study NCT02683798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Continuous energy restriction
Description: 1 x formula food (202-209kcal) meal replacement per day
Study NCT02232945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo of Banlangen(Radix Isatidis) granules
Study NCT02232945 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of Banlangen(Radix Isatidis) granules
Study NCT02893163 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHANGE Intervention
Description: Canadian Health Advanced by Nutrition and Graded Exercise Protocol
Study NCT02683798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Description: 4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
Study NCT03008213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netupitant and Palonosetron
Description: 300 mg of netupitant and 0.5 mg of palonosetron
Study NCT03418363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHEA Oral Capsule
Description: Daily 100mg DHEA supplement
Study NCT03275103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as premedication during Cycle 1.
Study NCT04794179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Naida Link CROS
Description: Individuals 18+ who already have Advanced Bionics CII/90K/Ultra cochlear implants will be given Naida Link CROS device to assess the effect the device has on speech understanding in challenging listening situations and on the quality of life in unilateral cochlear implant recipients and their frequent communication partners.
Study NCT02893163 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care by Family Doctor
Study NCT03531450 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings, and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. Patients will also learn behavioral strategies to decrease avoidance behavior and increase toleration of physical sensations.
Study NCT03742063 — intervention group
Intervention type: DRUG
Intervention: first-line chemotherapy
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
Study NCT03050840 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Way to Health
Description: An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
Study NCT03050840 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Way to Health
Description: An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
Study NCT02977143 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid loading of volulyte 300 ml
Description: Administration of volulyte 300 ml and measurement of increase in cardiac index
Study NCT02790658 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Intake of grumixama juice
Description: In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
Study NCT03548480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention with a daily dose of placebo
Study NCT03563638 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 75gOGTT
Description: oral glucose tolerance test (OGTT) was conducted on all participants between the 24th and 28th gestation weeks.The diagnosis of GDM is made when any of the following plasma glucose values are met or exceeded: FPG≥5.1 mmol/L and/or 1h-PG ≥10.0 mmol/L and/or 2h-PG ≥8.5 mmol/ L.
Study NCT03548480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Intervention with a daily dose of probiotic
Study NCT02368262 — intervention group
Intervention type: OTHER
Intervention: Questionnaire and micturition and drinking diaries
Description: Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.~Diaries: 24-hour voiding chart
Study NCT02368262 — intervention group
Intervention type: PROCEDURE
Intervention: Uroflowmetry, pelvic floor EMG and bladderscan
Description: Voiding variables, pelvic floor activity during micturition and postmictional residue.
Study NCT02383706 — intervention group
Intervention type: DEVICE
Intervention: ApneaLink Air
Description: Overnight, home polysomnography device
Study NCT02383706 — intervention group
Intervention type: BEHAVIORAL
Intervention: Berlin Quesionnaire
Description: OSA screening questionnaire
Study NCT02383706 — intervention group
Intervention type: BEHAVIORAL
Intervention: Epworth Sleepiness Scale
Description: OSA screening questionnaire
Study NCT02383706 — intervention group
Intervention type: BEHAVIORAL
Intervention: STOP-BANG questionnaire
Description: OSA screening questionnaire
Study NCT02383706 — intervention group
Intervention type: OTHER
Intervention: Physical exam
Description: Physical exam of neck, mouth and upper airway
Study NCT00924963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-Tip jet injector
Description: 0.2ml 1%buffered lidocaine delivered by jet injector
Study NCT00924963 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Jet injection saline
Description: 0.2ml saline delivered via J-Tip jet injection
Study NCT00924963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine cream
Description: 4% lidocaine cream applied for 30 minutes to the skin
Study NCT04476563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Obtaining biological samples
Description: Biological samples (blood, urine, stool). Liver tissue will be obtained from ChILI group when clinically indicated
Study NCT04667390 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty
Description: total knee arthroplasty
Study NCT01715779 — intervention group
Intervention type: DRUG
Intervention: Eltrombopag
Description: Eltrombopag exposure
Study NCT01742403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: R/T gating kV intrafraction monitoring
Description: This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
Study NCT02413008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol
Description: 0.005% estriol vaginal gel
Study NCT02413008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo vaginal gel
Study NCT02941939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric chamber
Study NCT02941939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambient pressure
Study NCT00904280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymorphone ER
Description: Open label
Study NCT01494090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 5 or 20 mg per day during 6 months
Study NCT01494090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 or 20 mg per day during 6 months
Study NCT02702635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI of the brain
Description: An MRI of the brain including a DCE sequence
Study NCT03136562 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Synacthen test
Description: 250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
Study NCT02654106 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated Stereotactic Radiotherapy
Description: The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
Study NCT02654106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles
Study NCT00308061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02A
Description: FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
Study NCT03418363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Daily oral capsule
Study NCT01783808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Description: Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.~In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used.
Study NCT00308061 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Imovax Rabies Vaccine
Description: Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, \<150g of neomycin sulfate, and >2.5 IU of rabies antigen.